Avalon GloboCare Announces Filing of Provisional Patent Applications for AVA-101, a Novel Transposon-Based, Multi-Targeted CAR-T Therapy Feb 26, 2019
Avalon GloboCare Announces Breakthrough in Identifying Human Angiogenic Exosomes/Extracellular Vesicles (EV) Derived from Endothelial Cells Feb 11, 2019
Avalon GloboCare CEO David Jin, M.D., Ph.D. to Co-Chair the “Status of Cellular Therapy in the Asia Pacific Rim” Session at the Annual Meetings of the Transplantation and Cellular Therapy (TCT) -- ASBMT and CIBMTR Tandem Meeting 2019 Feb 4, 2019
Avalon GloboCare and its Subsidiary Genexosome Technologies Announce Discovery and Development of World’s First Saliva-Based Exosomal Biomarker “miR-185” as Dual Diagnostic and Therapeutic Target for Oral Cancer Jan 28, 2019
Avalon GloboCare CEO David Jin, M.D., Ph.D. to Chair and Speak at the Plenary Session of the 14th Annual World Stem Cell Summit Jan 15, 2019
Avalon GloboCare Establishes Joint Venture with Arbele Limited to Co-develop Next-Generation Multi-Targeted CAR-T Cellular Immunotherapy Jan 3, 2019
Avalon GloboCare to Ring the Nasdaq Stock Market Closing Bell on January 7, 2019 at 4:00 PM Eastern Dec 19, 2018
Avalon GloboCare Provides Third Quarter 2018 Business Update; Reports 30% Increase in Revenues Nov 13, 2018
